Sleep Laboratories Reopening and COVID-19: A European Perspective.

Schiza S, Simonds A, Randerath W, Fanfulla F, Testelmans D, Grote L, Montserrat JM, Pepin JL, Verbracken J, Ersu R, Bonsignore MR

Eur Respir J - (-) - [2020-11-19; online 2020-11-19]

The clinical activities regarding sleep disordered breathing (SDB) have been sharply interrupted during the initial phase of the COVID-19 epidemic throughout Europe. In the last months, activities have gradually restarted, according to epidemiological phase of COVID-19 and National recommendations. The recent increase in cases throughout Europe obliges to reconsider management strategies of SDB accordingly. Diagnosis of SDB and initiation of treatment pose some specific problems to be addressed to preserve safety of the patients and health personnel. This perspective document by a group of European sleep experts aims at summarising some different approaches followed in Europe and United States, which reflect National recommendations according to the epidemiological phase of the COVID-19 infection. Respiratory sleep medicine will likely change in the near future, and use of telemedicine will grow to avoid unnecessary risks and continue to provide optimal care to the patients. The document also covers pediatric sleep studies and indications for titration of noninvasive ventilation, as well as precautions to be followed by patients who are already on positive airway pressure treatment. A single consensus document developed by the European Respiratory Society and National Societies would be desirable to harmonise SDB management throughout Europe.

Type: Other

PubMed 33214202

DOI 10.1183/13993003.02722-2020

Crossref 10.1183/13993003.02722-2020

pii: 13993003.02722-2020
pmc: PMC7683791


Publications 7.1.2